bio sketch column
Matthew Shair is a Professor in the Department of Chemistry and Chemical Biology at Harvard University, an associate of the Broad Institute and an affiliate of the Harvard Stem Cell Institute. His lab studies the mechanistic basis of human diseases, identifies new targets, and develops small molecule therapeutics. His laboratory has discovered that inhibition of CDK8 and CDK19 is a new therapeutic approach to acute myeloid leukemia (AML) involving unanticipated effects on transcription of cell identity genes. He has also used small molecules to discover that oxysterol-binding proteins are a druggable dependency of solid tumor cells. His lab is known for their creative synthesis of complex naturally occurring molecules. He has been the recipient of several awards for his work, most notably the Raymond and Beverly Sackler Prize in the Physical Sciences-Chemistry administered by Tel Aviv University and the Arthur C. Cope Scholar Award. He has been a founder of several biotech companies including Infinity Pharmaceuticals (Nasdaq: INFI), Makoto Life Sciences and Chemiderm. He has also been an advisor to Ariad, Enanta, Bristol-Myers Squibb and Novartis. Molecules created in his lab for the treatment of cancer have been licensed by Merck in one of the largest licensing deals of an academic preclinical asset.